Study of TUB-040 with Standard Ovarian Cancer Drugs for Fast-growing Ovarian Cancer

Inclusion Criteria

• Women aged 18 or older.
• Good overall health with an ECOG performance status of 0 or 1.
• Diagnosed with advanced high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
• Cancer that has responded to platinum-based treatments and has not worsened within 6 months after the last treatment.
• At least one tumor that can be measured by scans.
• Cancer must have shown progression on or after the most recent treatment.
• Adequate blood cell counts and liver and kidney function.
• Willing to provide a tumor sample for research purposes.
• Resolved side effects from previous treatments to a mild level.
• Completed a washout period after previous treatments.
• Women of childbearing potential must use effective contraception during the study and for a specified period after.
• Must have had 1-2 prior lines of platinum therapy without progression within 182 days after the last dose.
• Prior treatment with PARP inhibitors if applicable.

Exclusion Criteria

• Certain types of ovarian cancer, such as clear-cell or mucinous.
• Cancer that did not respond to or worsened quickly after platinum-based treatments.
• Pregnant or breastfeeding women.
• History of severe allergic reactions to study drugs.
• Unresolved bowel obstruction or certain abdominal conditions.
• Recent major surgery or other clinical trial participation.
• Certain lung or heart conditions.
• Active infections or other serious health issues.
• Recent use of live vaccines.
• History of severe blood clots or uncontrolled high blood pressure.
• Requirement to take certain medications that interact with the study drugs.